For patients
Anifrolumab
Saphnelo, anti-IFNAR1, type I interferon receptor antagonist
Are you a clinician? See the clinical version of this page.
The short versionAnifrolumab (Saphnelo) is a lupus medicine that blocks the type I interferon signal, which is overactive in many people with lupus. It is added to your usual treatment to lower disease activity and flares. Because pregnancy data are limited and it is not recommended during pregnancy, planning ahead with your team matters if you may become pregnant.
- The decision balances controlling lupus against limited pregnancy data.
Through your pregnancy journey
Individualise
Before pregnancy
Plan ahead with your team. Because it is not recommended in pregnancy, a switch to a pregnancy-compatible medicine is usually arranged before conception.
Avoid
First trimester
Not recommended during pregnancy.
Avoid
Second & third trimester
Not recommended during pregnancy.
Individualise
Breastfeeding
Breastfeeding data are limited; discuss with your team.
Individualise
For fathers-to-be
For fathers-to-be, data are limited; discuss with your team.
iThis page helps you prepare a conversation with your care team. It does not replace individual medical advice. Always confirm your own plan with your rheumatology and pregnancy team.
!
When to call your team
- Do not stop or start anifrolumab without your team.
- Tell your team promptly about any signs of infection, including a painful blistering rash (shingles).